SPL Medical, based at the Novio Tech Campus in Nijmegen, is starting an international registration study for its contrast agent ferrotran. The study, which aims to demonstrate the diagnostic efficacy of the agent, is being conducted in ten hospitals in Germany, Switzerland and the Netherlands, including Radboudumc.
Mini-metastases in the picture
Ferrotran is a product of the Radboudumc spin-off SPL Medical. The contrast agent makes very small metastases in the lymph nodes highly visible on MRI scans. Even mini-metastases less than two millimeters in diameter can be detected with this approach. The drug consists of nano-iron particles, which make normal lymph nodes on an MRI scan appear black, while abnormal glands appear white. This makes it very easy to distinguish them from each other. Because ferrotran also makes the lymph vessels visible, the mini-metastases can be located with outstanding accuracy. This enables treatment – for example with targeted radiotherapy – at an early stage, resulting in fewer side effects and improving the chance of a cure. Other diagnostic techniques are limited in resolution to four to six millimeters and cannot detect such small metastases.
The first version of the product was developed in the USA in the late 1990s. Jelle Barentsz, professor of Functional Imaging at Radboudumc, discovered the value of this drug in patients with lymph node metastases. "He managed to obtain the rights for the drug for Radboudumc," says Harrie van Baars, Chief Business Officer at SPL Medical. "He then continued developing the product to make very small metastases visible."
According to Barentsz, clinical studies at Radboudumc have included hundreds of patients with various forms of cancer, such as cancer of the rectum, esophagus, pancreas, head-and-neck and prostate. "The results were so encouraging," he says, "that the product was privatized in 2015 with the spin-off SPL Medical."
Although a great deal of research data on ferrotran has been published in scientific journals, the product has not yet been authorized for the market. This requires a clinical registration study, which is now beginning. Van Baars: “This study is the prelude to the official authorization and market introduction of the product in Europe. We will study the use of ferrotran in 180 patients in ten hospitals in Germany, Switzerland and the Netherlands, including Radboudumc."
Although the agent has not yet been authorized for the market, it can sometimes be used for approved clinical studies, such as those taking place at Radboudumc. Some hospitals can also use the agent under strict conditions as part of a ‘compassionate use’ program for patients with life-threatening, long-lasting or seriously debilitating illnesses. Van Baars: “In that context, the first patient with metastatic prostate cancer in Switzerland has recently received ferrotran. With the clinical trial and the compassionate use program, our goal of making ferrotran widely available for cancer patients has come much closer to realization.”
Related news items
650,000 Euro funding for research into the phasing out of medication for leukaemia patients30 July 2020
With a 650,000 euro funding from ZonMw, researchers from the Haematology and Pharmacy departments can develop a medication phasing out strategy for patients with chronic myeloid leukaemia. This strategy will be tested in practice.read more
Increased role of patients after bowel cancer treatment30 July 2020
Approximately 14,000 patients get colorectal cancer every year. Almost all patients are operated on and monitored afterwards (follow-up). In 2019 Radboudumc started a new approach to follow-up research after the treatment of stage II/III colorectal cancer.read more
ERC Proof of Concept grant received by Ronald van Rij30 July 2020
Ronald van Rij, theme Infectious diseases and global health, received an ERC (European Research Council) Proof of Concept grant of 150,000 euros, in order to make arbovirus vaccines even safer.read more
Hypatia fellowship Call is open30 July 2020
The Hypatia fellowship round with the deadline 31 May has been canceled. Therefore, the next available deadline will be 27 September 2020. Radboudumc researchers are invited to scout young potentials to fill the strategic gaps within the research themes imbedded in RIHS and RIMLS.read more
Mihai Netea and colleagues published two papers back-to-back in The Journal of Clinical Investigation.29 July 2020
These back-to-back articles investigated the effect of BCG vaccination on trained immunity. The first article shows that BCG vaccination inhibits systemic inflammation, depending on gender. The second article demonstrates that the circadian rhythm influences the induction of trained immunity.read more
Genetic mutation reveals how coronavirus strikes TLR7 plays essential role in disease process28 July 2020
''Does a congenital immune defect play an important role in the defense against Coronavirus?'' This was published by Cas van der Made, Frank van der Veerdonk and Alexander Hoischen.read more